Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | CCKAR | P32238 | 1/20 | 0.35 |
| ▸ | CCKBR | P32239 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422040 | 0.90 | IKBKB (0.47) | IKBKBSCN9ACCKARCCKBRKDM4E | |
| SCHEMBL29668334 | 0.90 | IKBKB (0.47) | IKBKBSCN9ACCKARCCKBRKDM4E | |
| Hydrochloric Acid SCHEMBL14843117 | 0.89 | IKBKB (0.46) | IKBKBSCN9ACCKARCCKBRKDM4E | |
| SCHEMBL27808756 | 0.89 | IKBKB (0.46) | IKBKBSCN9ACCKARCCKBRKDM4E | |
| SCHEMBL28088528 | 0.82 | IKBKB (0.39) | IKBKBSCN9ACCKARCCKBRCHEK1 | |
| Pyridine SCHEMBL17099679 | 0.81 | IKBKB (0.41) | IKBKBSCN9AKDM4EHSD17B10MGAM | |
| Hydrochloric Acid SCHEMBL14844844 | 0.80 | IKBKB (0.40) | IKBKBHCRTR1HCRTR2SCN9ACCKAR | |
| SCHEMBL2915555 | 0.77 | IKBKB (0.38) | IKBKBSCN9ACCKARCCKBRCHEK1 | |
| SCHEMBL10559629 | 0.77 | IKBKB (0.41) | IKBKBCCKARCCKBRKDM4EHSD17B10 | |
| SCHEMBL5350724 | 0.74 | MGAM (0.42) | IKBKBCCKARCCKBRKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024033513-A1 | COMPOUNDS FOR TREATING CANCER | DIACCURATE (FR) | 2024-02-15 | — | — | WO | claimed |
| CN-118354776-A | Methods and compositions for enhanced efficacy and reduced toxicity of non-implanted CD8 depleted allogeneic donor lymphocyte infusions | 约翰霍普金斯大学 | 2024-07-16 | — | — | CN | disclosed |
| WO-2024073529-A1 | METHODS AND COMPOSITIONS FOR LOCALIZED PRODUCTION AND DELIVERY OF BIOLOGICAL MOLECULES | IYUDA THERAPEUTICS, LLC (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024072998-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE CELL THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024033513-A1 | COMPOUNDS FOR TREATING CANCER | DIACCURATE (FR) | 2024-02-15 | — | — | WO | disclosed |
| WO-2024033513-A1 | COMPOUNDS FOR TREATING CANCER | DIACCURATE (FR) | 2024-02-15 | — | — | WO | disclosed |
| WO-2023055942-A1 | METHODS AND COMPOSITIONS TO AUGMENT EFFICACY AND REDUCE TOXICITY OF NON-ENGRAFTING, CD8-DEPLETED ALLOGENIC DONOR LYMPHOCYTE INFUSIONS | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20230097340-A1 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | PHARMACYCLICS LLC (US) | 2023-03-30 | — | — | US | disclosed |
| US-20230100137-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | PHARMACYCLICS LLC (US) | 2023-03-30 | — | — | US | disclosed |
| EP-4115886-A1 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | Pharmacyclics LLC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20140134265-A1 | TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY | PHARMACYCLICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| WO-2014071231-A1 | TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY | PHARMACYCLICS, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| JP-2013544257-A | — | — | 2013-12-12 | — | — | JP | disclosed |
| EP-2643313-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | Merck Patent GmbH (DE) | 2013-10-02 | — | — | EP | disclosed |
| EP-2643313-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | Merck Patent GmbH (DE) | 2013-10-02 | — | — | EP | disclosed |
| US-20130252942-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| US-20130252942-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| CN-103228649-A | Quinazoline carboxamide azetidines | MERCK PATENT GMBH | 2013-07-31 | — | — | CN | disclosed |
| WO-2012069146-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012069146-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230097340-A1 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | BLK, DCK, CILK1 | IKBKB 263/4885CHRNB2 4592/4885CHRNA4 4808/4885 |
| US-20230100137-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | FCGR3B, BTK, IGLV6-57 | IKBKB 185/4885CHRNB2 4506/4885CHRNA4 4830/4885 |
| US-20130252942-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | AZI2, NQO2, ABL1 | IKBKB 2292/4885CHRNB2 2586/4885CHRNA4 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.